Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer

Inclusion Criteria: * Radiologic confirmation of unresectable pancreatic cancer by at least CT of chest and abdomen * Screening must be performed no longer than 2 weeks prior to study inclusion * Maximum tumor diameter ≤ 5 cm; * Histological or cytological confirmation of pancreatic adenocarcinoma; * Age ≥ 18 years; * ASA-classification 0 - 3 * Life expectancy of at least 12 weeks; * Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to definite inclusion; * Hemoglobin ≥ 5.6 mmol/L; * Absolute neutrophil count (ANC) ≥ 1,500/mm3; * Platelet count ≥ 100\*109/l; * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); * ALT and AST ≤ 2.5 x ULN; * Serum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance ≥ 50 ml/min; * Prothrombin time or INR \< 1.5 x ULN; * Activated partial thromboplastin time \< 1.25 x ULN (therapeutic anticoagulation therapy is allowed if this treatment can be interrupted as judged by the treating physician); * Written informed consent; Exclusion Criteria: * Resectable pancreatic adenocarcinoma as discussed by our multidisciplinary hepatobiliary team; * Successful down staging after (radio)chemotherapy from previous unresectable/borderline tumor to resectable tumor; * History of epilepsy; * History of cardiac disease: * Congestive heart failure \>NYHA class 2; * Active Coronary Artery Disease (defined as myocardial infarction within 6 months prior to screening); * Cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers for antihypertensive regimen are permitted); * Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen; * Compromised liver function (e.g. signs of portal hypertension, INR \> 1,5 without use of anticoagulants, ascites); * Uncontrolled infections (\> grade 2 NCI-CTC version 3.0); * Pregnant. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment; * Immunotherapy ≤ 6 weeks prior to the procedure; * Chemotherapy ≤ 6 weeks prior to the procedure; * Radiotherapy ≤ 6 weeks prior to the procedure; * Concomitant use of anti-convulsive and anti-arrhythmic drugs (other than beta blockers used for antihypertensive); * Allergy to contrast media; * Any implanted stimulation device; * Any implanted metal stent/device within the area of ablation that cannot be removed; * Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study; Of note, patients with contra-indications for MRI will not be excluded from participation: in this case radiologic follow-up will consist of CT-scanning according to protocol.